Investor Presentation First Nine Months of 2023
22
Investor presentation
First nine months of 2023
Novo Nordisk has leading positions in diabetes, obesity and
haemophilia
Novo NordiskⓇ
Diabetes care
DKK
billion
1200
1000
800
Obesity care
DKK
billion
#1
50%
60
40%
50
50
40
40
30%
Haemophilia
DKK
billion
#1
120%
100
#3
50%
100%
80
40%
80%
60
30%
600
50
30
60%
20%
40
400
20
40
20%
20
40%
CAGR¹ value: 16.6%
10%
CAGR² value: 121.4%
20
200
10
20%
20
10%
CAGR³ value: 5.9%
0
0%
0
0%
0
Aug
2018
Aug
2023
Aug
2021
Aug
2023
FY
2019
0%
FY
2022
Market value
NN value market share (RHS)
Market value
Market value
Global market position
NN value market share (RHS)
Global market position
-NN value market share (RHS)
Global market position
1 CAGR for 5-year period; 2 CAGR for 2-year period; ³ CAGR for 3-year period; RHS: Right-hand side; Note: Annual sales figures for haemophilia A, B and bypassing agent segments, plasma derived products excluded except FeibaⓇ;
Source: Company reports for haemophilia market; IQVIA MAT, Aug 2023; Note: Market values are based on the list prices
NN: Novo Nordisk.View entire presentation